PMC:4134656 / 13548-14103 JSONTXT

{"project":"2_test","denotations":[{"id":"25136206-18550886-58659546","span":{"begin":279,"end":281},"obj":"18550886"},{"id":"25136206-22097156-58659547","span":{"begin":388,"end":390},"obj":"22097156"},{"id":"25136206-23405852-58659548","span":{"begin":388,"end":392},"obj":"23405852"},{"id":"25136206-21261702-58659549","span":{"begin":388,"end":394},"obj":"21261702"},{"id":"25136206-19706583-58659550","span":{"begin":388,"end":396},"obj":"19706583"},{"id":"25136206-20117846-58659551","span":{"begin":388,"end":398},"obj":"20117846"},{"id":"25136206-23278381-58659552","span":{"begin":388,"end":400},"obj":"23278381"},{"id":"25136206-21995836-58659553","span":{"begin":388,"end":402},"obj":"21995836"},{"id":"25136206-22944359-58659554","span":{"begin":388,"end":404},"obj":"22944359"},{"id":"25136206-22967870-58659555","span":{"begin":388,"end":406},"obj":"22967870"},{"id":"25136206-21788220-58659556","span":{"begin":388,"end":408},"obj":"21788220"},{"id":"25136206-21362031-58659557","span":{"begin":388,"end":410},"obj":"21362031"},{"id":"25136206-21108669-58659558","span":{"begin":388,"end":412},"obj":"21108669"},{"id":"25136206-22132796-58659559","span":{"begin":388,"end":414},"obj":"22132796"},{"id":"25136206-22498385-58659560","span":{"begin":388,"end":418},"obj":"22498385"},{"id":"25136206-23278381-58659561","span":{"begin":552,"end":554},"obj":"23278381"}],"text":"Propranolol is a non-selective -β adrenergic receptor blocker that recently has emerged as a good therapeutic option in IH. In 2008, Leaute-Labreze et al. reported regression of a facial IH in a child who was treated with propranolol for obstructive hypertrophic cardiomyopathy.[25] Ever since there has been a series of publications describing its therapeutic efficacy and side effects.[262728293031323334353637383940] Currently, it is widely used in IH, particularly for complicated and ulcerated IH, and appears to be the best therapeutic modality.[31]"}